Literature DB >> 8276287

Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer.

P Benedetti-Panici1, S Greggi, F Maneschi, G Scambia, M Amoroso, C Rabitti, S Mancuso.   

Abstract

The pattern of lymphatic spread was evaluated in 81 previously untreated ovarian cancer patients (Stage I, 35; Stage II, 2; Stage III, 44) undergoing systematic aortic and pelvic lymphadenectomy. Positive nodes were found in 14% Stage I and 68% Stage III patients. Either pre- and paraaortic, or pre- and paracaval nodes were the only aortic node metastasis in 14% of patients. Common iliac nodes were the sole metastasis in pelvic area in 11%, external iliac in 14%, and obturator in 6% of patients. Therefore, the above node groups, which overall were the most frequently involved, may be considered those primarily invaded by the tumor. When data were analyzed according to stage, aortic nodes were the site of metastasis in 6% Stage I and 14% Stage III patients and pelvic nodes in 8% Stage I and 11% Stage III patients. Both aortic and pelvic areas were positive in 43% Stage III patients. The median number of positive nodes/patient was 2 (range, 1-3) and 4 (range 2-46) in Stages I and III, respectively. Lymphatic spread was ipsilateral to the tumor in all Stage I and in 40% Stage III patients. In Stage III metastases were also observed in intercavoaortic, retrocaval, retroaortic, internal iliac, and presacral nodes. In apparent Stage I, lymphatic metastasis seemed to be limited to one ipsilateral group, and the removal of the primary nodes ipsilateral to the tumor may be considered an adequate procedure. In Stage III, the presence of metastasis beyond the primary nodes and the frequent bilateral involvement suggest that all lymphatic tissue surround the aorta, the cava, and the pelvic vessels should be removed if a cytoreductive intent is pursued.

Entities:  

Mesh:

Year:  1993        PMID: 8276287     DOI: 10.1006/gyno.1993.1263

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

Review 1.  Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.

Authors:  Kimio Ushijima
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

Review 2.  Lymphadenectomy in Ovarian Cancer: Is It Still Justified?

Authors:  Pierluigi Benedetti Panici; Andrea Giannini; Margherita Fischetti; Francesca Lecce; Violante Di Donato
Journal:  Curr Oncol Rep       Date:  2020-02-08       Impact factor: 5.075

3.  What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Authors:  Bunja J Rungruang; Austin Miller; Thomas C Krivak; Neil S Horowitz; Noah Rodriguez; Chad A Hamilton; Floor J Backes; Linda F Carson; Michael Friedlander; David G Mutch; Michael J Goodheart; Krishnansu S Tewari; Robert M Wenham; Michael A Bookman; G Larry Maxwell; Scott D Richard
Journal:  Cancer       Date:  2016-11-16       Impact factor: 6.860

4.  Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.

Authors:  Shanshan Yang; Huiyan Li; Yunduo Liu; Xiaoming Ning; Fanling Meng; Min Xiao; Deying Wang; Ge Lou; Yunyan Zhang
Journal:  Med Oncol       Date:  2012-12-18       Impact factor: 3.064

Review 5.  Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI.

Authors:  Rosemarie Forstner
Journal:  Eur Radiol       Date:  2007-08-14       Impact factor: 5.315

6.  Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer.

Authors:  Su-Jin Baek; Jeong-Yeol Park; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

7.  Sentinel node in ovarian cancer: study protocol for a phase 1 study.

Authors:  Marjolein Kleppe; Toon Van Gorp; Brigitte F M Slangen; Arnold J Kruse; Boudewijn Brans; Ivo N A Pooters; Koen K Van de Vijver; Roy F P M Kruitwagen
Journal:  Trials       Date:  2013-02-15       Impact factor: 2.279

8.  Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature.

Authors:  Guldeniz Aksan Desteli; Murat Gultekin; Alp Usubutun; Kunter Yuce; Ali Ayhan
Journal:  World J Surg Oncol       Date:  2010-11-30       Impact factor: 2.754

9.  Utility of Intraoperative Fluorescence Imaging in Gynecologic Surgery: Systematic Review and Consensus Statement.

Authors:  Ignacio Zapardiel; Julio Alvarez; Manel Barahona; Pere Barri; Ana Boldo; Pera Bresco; Isabel Gasca; Ibon Jaunarena; Ali Kucukmetin; Gloria Mancebo; Borja Otero; Fernando Roldan; Ramón Rovira; Enma Suarez; Alvaro Tejerizo; Anna Torrent; Mikel Gorostidi
Journal:  Ann Surg Oncol       Date:  2020-10-23       Impact factor: 5.344

10.  Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Authors:  T Dell' Anna; M Signorelli; P Benedetti-Panici; A Maggioni; R Fossati; R Fruscio; R Milani; L Bocciolone; A Buda; C Mangioni; G Scambia; R Angioli; E Campagnutta; R Grassi; F Landoni
Journal:  Br J Cancer       Date:  2012-08-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.